Summary
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
Gossamer Bio's experimental lung condition drug fails in late-stage trial
Gossamer Bio said on Monday its experimental drug missed the main goal of a late-stage study in patients with a serious lung and heart condition.
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.14 per share a year ago.
Gossamer Bio Inc. (GOSS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Gossamer Bio Inc. ever had a stock split?
Gossamer Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Faheem Hasnain CEO | NASDAQ (NGS) Exchange | 38341P102 CUSIP |
| US Country | 144 Employees | - Last Dividend | - Last Split | 8 Feb 2019 IPO Date |
Overview
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company with a sharp focus on the discovery, acquisition, development, and commercialization of therapeutic solutions. The company's efforts are primarily directed towards addressing critical needs within the domains of immunology, inflammation, and oncology in the United States. Originally established as FSG, Bio, Inc., the company underwent a rebranding to become Gossamer Bio, Inc. in 2017. Incorporated in 2015 and based in San Diego, California, Gossamer has established itself as a key player in the biopharmaceutical industry, leveraging its expertise and strategic partnerships to bring innovative treatments from the lab to the market.
Products and Services
- GB002 - Inhaled Pulmonary Arterial Hypertension Treatment
- GB004 - Oral Treatment for Inflammatory Bowel Disease
- GB5121 - Primary Central Nervous System Lymphoma Therapy
- GB7208 - Oral Multiple Sclerosis Treatment
An advanced, inhaled small molecule therapy, GB002 is designed to inhibit the activity of the platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This compound is being developed as a new treatment option for pulmonary arterial hypertension, aiming to improve patient outcomes by targeting key pathways involved in the disease's pathogenesis.
GB004 represents Gossamer's commitment to addressing inflammatory bowel disease (IBD) through an innovative, gut-targeted, oral small molecule therapy. By focusing on the gut, this treatment has the potential to provide relief and management for individuals suffering from IBD, offering a new avenue of hope for patients with this chronic condition.
This oral, irreversible, covalent small molecule inhibitor targets Bruton's Tyrosine Kinase (BTK), a key enzyme in the B cell receptor signaling pathway. GB5121 is designed for the treatment of primary central nervous system lymphoma, aiming to offer a targeted therapeutic approach to combat this particularly aggressive type of brain tumor.
As a small molecule BTK inhibitor, GB7208 offers a new oral treatment option for multiple sclerosis (MS). By inhibiting the BTK enzyme, GB7208 is poised to play a crucial role in the management of MS, providing patients with a potentially effective tool against this chronic autoimmune disease that affects the central nervous system.
In pursuit of its goals, Gossamer Bio, Inc. has entered into strategic licensing agreements with Pulmokine, Inc. for the development and commercialization of GB002 and related compounds, as well as with Aerpio Pharmaceuticals, Inc. for GB004 and related compounds. These partnerships underscore the company's commitment to bringing novel, life-changing treatments to patients in need.
